Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review

Aleš Tichopád, Juliana Müllerová, Teresa Jackowska, E. Nemes, Petr Pazdiora, Brigitte Sloesen, Mária Štefkovičová

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. Methods We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. Results The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use–driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. Conclusions Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalValue in Health Regional Issues
Volume10
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Slovakia
Hungary
Rotavirus
Czech Republic
Gastroenteritis
Poland
Hospitalization
Costs and Cost Analysis
Diagnosis-Related Groups
Costs
Charts
Burden
Slovak Republic
Economics
Health Expenditures
Health Care Costs
Inpatients
Length of Stay
Decision Making
Vaccination

Keywords

  • chart review
  • cost burden
  • incidence
  • rotavirus gastroenteritis
  • vaccination
  • Visegrad region

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary : A Retrospective Patient Chart Review. / Tichopád, Aleš; Müllerová, Juliana; Jackowska, Teresa; Nemes, E.; Pazdiora, Petr; Sloesen, Brigitte; Štefkovičová, Mária.

In: Value in Health Regional Issues, Vol. 10, 01.09.2016, p. 53-60.

Research output: Contribution to journalArticle

Tichopád, Aleš ; Müllerová, Juliana ; Jackowska, Teresa ; Nemes, E. ; Pazdiora, Petr ; Sloesen, Brigitte ; Štefkovičová, Mária. / Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary : A Retrospective Patient Chart Review. In: Value in Health Regional Issues. 2016 ; Vol. 10. pp. 53-60.
@article{626fcf28430e466c881b672a9ab5f11a,
title = "Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review",
abstract = "Objectives To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. Methods We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. Results The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use–driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. Conclusions Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.",
keywords = "chart review, cost burden, incidence, rotavirus gastroenteritis, vaccination, Visegrad region",
author = "Aleš Tichop{\'a}d and Juliana M{\"u}llerov{\'a} and Teresa Jackowska and E. Nemes and Petr Pazdiora and Brigitte Sloesen and M{\'a}ria Štefkovičov{\'a}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.vhri.2016.07.005",
language = "English",
volume = "10",
pages = "53--60",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary

T2 - A Retrospective Patient Chart Review

AU - Tichopád, Aleš

AU - Müllerová, Juliana

AU - Jackowska, Teresa

AU - Nemes, E.

AU - Pazdiora, Petr

AU - Sloesen, Brigitte

AU - Štefkovičová, Mária

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objectives To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. Methods We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. Results The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use–driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. Conclusions Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

AB - Objectives To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. Methods We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. Results The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use–driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. Conclusions Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

KW - chart review

KW - cost burden

KW - incidence

KW - rotavirus gastroenteritis

KW - vaccination

KW - Visegrad region

UR - http://www.scopus.com/inward/record.url?scp=84986893077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986893077&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2016.07.005

DO - 10.1016/j.vhri.2016.07.005

M3 - Article

C2 - 27881278

AN - SCOPUS:84986893077

VL - 10

SP - 53

EP - 60

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -